Human Hookworm Vaccine

Abstract

A vaccine for human hookworm is provided. The vaccine comprises at least one L3 larval stage antigen (e.g. Na-ASP-2 or Na-SAA-2) and at least one adult stage human hookworm antigen (e.g. Na-APR-1, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or Na-GST-1) and adjuvants.

1 . A vaccine composition, comprising,
 at least one larval-stage hookworm antigen;   at least one adult-stage hookworm antigen;   an aluminum-based adjuvant; and   a second adjuvant.   
     
     
         2 . The vaccine composition of  claim 1 , wherein said larval-stage hookworm antigen is selected from the group consisting of Na-ASP-2 and Na-SAA-2, or antigenic fragments thereof. 
     
     
         3 . The vaccine composition of  claim 1 , wherein said adult-stage hookworm antigen is selected from the group consisting of Na-APR-1, Na-GST, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or antigenic fragments thereof. 
     
     
         4 . The vaccine of  claim 3 , wherein said Na-APR-1 is  Pichia  optimized Na-APR-1, or an antigenic fragment thereof. 
     
     
         5 . The vaccine composition of  claim 1 , wherein said aluminum-based adjuvant is Alhydrogel®. 
     
     
         6 . The vaccine composition of  claim 1 , wherein said second adjuvant is selected from the group consisting of: CpG and Synthetic lipid A. 
     
     
         7 . The vaccine composition of  claim 1 , wherein said aluminum-based adjuvant and said second adjuvant are combined together. 
     
     
         8 . A method for vaccinating a patient in need thereof against hookworm infections, comprising the step of
 administering to said patient a vaccine composition comprising,
 at least one larval-stage hookworm antigen; 
 at least one adult-stage hookworm antigen; 
 an aluminum-based adjuvant; and 
 a second adjuvant. 
   
     
     
         9 . The method of  claim 8 , wherein said larval-stage hookworm antigen is selected from the group consisting of Na-ASP-2 and Na-SAA-2, or antigenic fragments thereof. 
     
     
         10 . The method of  claim 8 , wherein said adult-stage hookworm antigen is selected from the group consisting of Na-APR-1, Na-GST, Na-CP-2, Na-CP-3, Na-CP-4, Na-CP-5, or antigenic fragments thereof. 
     
     
         11 . The method of  claim 10 , wherein said Na-APR-1 is  Pichia  optimized Na-APR-1, or an antigenic fragment thereof. 
     
     
         12 . The method of  claim 8 , wherein said aluminum-based adjuvant is Alhydrogel®. 
     
     
         13 . The method of  claim 8 , wherein said second adjuvant is selected from the group consisting of: CpG and Synthetic lipid A. 
     
     
         14 . The method of  claim 8 , wherein said aluminum-based adjuvant and said second adjuvant are combined together. 
     
     
         15 . The method of  claim 8 , further comprising the step of administering a deworming agent to said patient. 
     
     
         16 . A hookworm vaccine comprising
 a hookworm larval stage antigen;   an hookworm adult stage antigen; and   one or more adjuvants.   
     
     
         17 . A method for vaccinating a patient in need thereof against hookworm infections, comprising the step of
 administering to said patient a vaccine composition comprising,
 a hookworm larval stage antigen; 
 an hookworm adult stage antigen; and 
 one or more adjuvants.